Julian G. Hurdle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julian G. Hurdle has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Chetna Dureja
Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center
9 shared publicationsXiaoqian Wu
Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA
8 shared publicationsAditi Deshpande
Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA
7 shared publications- Kevin W. Garey
University of Houston College of Pharmacy
7 shared publications Wan-Jou Shen
Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, USA
6 shared publicationsAbiola O. Olaitan
5 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Revitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies
Clostridioides difficile infection (CDI) remains a leading cause of healthcare-associated diarrhea, arising largely from antimicrobial-induced displacement of the gut microbiota. Although antimicrobial therapy remains the clinical standard for CDI, high rates of recurrence, the spread of antimicrobial-resistant strains, and inadequate interventions for countering toxin-mediated tissue damage highlight the need for alternative strategies. In this review, we evaluate emerging nonantimicrobial approaches for CDI, focusing on microbial-derived metabolites (including short-chain fatty acids and bile acids), plant-derived phytochemicals, and host-directed therapeutics that modulate inflammatory and neuroimmune pathways. Mechanistic insights into how these strategies mitigate C. difficile pathogenesis are also examined, including roles in attenuating intestinal inflammation and preserving epithelial barrier function. Given the multifactorial nature of CDI, we propose there is a need to advance a new therapeutic framework that integrates narrow-spectrum antimicrobials with nonantimicrobial host-directed modalities. Collectively, this conceptual framework provides a rational foundation for developing next-generation interventions for CDI in an era characterized by multidrug resistance and aging populations with comorbidities that are risk factors for CDI.
- 13 November 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Open AccessRevitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies
Clostridioides difficile infection (CDI) remains a leading cause of healthcare-associated diarrhea, arising largely from antimicrobial-induced displacement of the gut microbiota. Although antimicrobial therapy remains the clinical standard for CDI, high rates of recurrence, the spread of antimicrobial-resistant strains, and inadequate interventions for countering toxin-mediated tissue damage highlight the need for alternative strategies. In this review, we evaluate emerging nonantimicrobial approaches for CDI, focusing on microbial-derived metabolites (including short-chain fatty acids and bile acids), plant-derived phytochemicals, and host-directed therapeutics that modulate inflammatory and neuroimmune pathways. Mechanistic insights into how these strategies mitigate C. difficile pathogenesis are also examined, including roles in attenuating intestinal inflammation and preserving epithelial barrier function. Given the multifactorial nature of CDI, we propose there is a need to advance a new therapeutic framework that integrates narrow-spectrum antimicrobials with nonantimicrobial host-directed modalities. Collectively, this conceptual framework provides a rational foundation for developing next-generation interventions for CDI in an era characterized by multidrug resistance and aging populations with comorbidities that are risk factors for CDI.
- Open Access
- 22 October 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (10)
An integrated view of metabolic and physiological regulation of toxin production in Clostridioides difficile
Clostridioides difficile is a leading cause of antibiotic-associated diarrhea, with pathogenesis driven primarily by the glucosylating toxins TcdA and TcdB. Traditionally, toxin gene expression has been explained through regulation of the pathogenicity locus by global transcriptional regulators that integrate nutrient availability, growth phase, and environmental signals. While this framework provides a foundation for understanding toxin regulation, recent advances have broadened this perspective to include diverse metabolic and physiological inputs, including carbon and amino acid metabolism, metal ion homeostasis, redox balance, and cellular energy status. Collectively, these factors suggest that toxin gene expression is a dynamic emergent property that reflects a high level of integration of metabolic and physiological networks. In this minireview, we discuss canonical mechanisms of toxin regulation alongside new insights that highlight population heterogeneity, energy demand conflicts, metabolic constraints, purine metabolism, and cross-regulatory networks linking sporulation and virulence. We further examine discoveries from small-molecule chemical genetics demonstrating that perturbation of metabolic pathways can suppress toxin biosynthesis without substantially affecting bacterial viability. Together, these findings redefine toxin regulation as a systems-level process in which metabolic and physiological states mediate toxin production and contribute to phenotypic heterogeneity. Elucidating these networks may reveal promising targets for the development of anti-virulence strategies for C. difficile infection.
- 22 October 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (10)
Open AccessAn integrated view of metabolic and physiological regulation of toxin production in Clostridioides difficile
Clostridioides difficile is a leading cause of antibiotic-associated diarrhea, with pathogenesis driven primarily by the glucosylating toxins TcdA and TcdB. Traditionally, toxin gene expression has been explained through regulation of the pathogenicity locus by global transcriptional regulators that integrate nutrient availability, growth phase, and environmental signals. While this framework provides a foundation for understanding toxin regulation, recent advances have broadened this perspective to include diverse metabolic and physiological inputs, including carbon and amino acid metabolism, metal ion homeostasis, redox balance, and cellular energy status. Collectively, these factors suggest that toxin gene expression is a dynamic emergent property that reflects a high level of integration of metabolic and physiological networks. In this minireview, we discuss canonical mechanisms of toxin regulation alongside new insights that highlight population heterogeneity, energy demand conflicts, metabolic constraints, purine metabolism, and cross-regulatory networks linking sporulation and virulence. We further examine discoveries from small-molecule chemical genetics demonstrating that perturbation of metabolic pathways can suppress toxin biosynthesis without substantially affecting bacterial viability. Together, these findings redefine toxin regulation as a systems-level process in which metabolic and physiological states mediate toxin production and contribute to phenotypic heterogeneity. Elucidating these networks may reveal promising targets for the development of anti-virulence strategies for C. difficile infection.
- Open Access
- 15 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1023
Cyclic di-GMP Regulation of Antibiotic-Induced Biofilm Formation: A Systematic Review
Background/Objectives: Biofilm formation is a major bacterial survival strategy in response to antibiotic stress. The bacterial second messenger cyclic di-GMP (c-di-GMP) is a central regulator of biofilm development. Sub-minimum inhibitory concentrations (sub-MICs) of antibiotics act as biological active environmental cues that reprogram bacterial physiology and promote biofilm development. This systematic review synthesizes the current literature on sub-MIC antibiotic-induced biofilm formation across different pathogenic bacterial genera and critically evaluates the role of c-di-GMP. Methods: A systematic literature search was conducted in PubMed and Scopus for articles published from inception to 18 December 2025 using terms including “sub-MIC antibiotic” AND (“biofilm” OR “antibiotic-induced biofilm”) and a second search using “sub-MIC antibiotic” AND “biofilm” AND “c-di-GMP”. Reviews, commentaries, opinions, meta-analyses, systematic reviews, and non-English-language articles were excluded. Results: Collectively, 28 identified studies demonstrate that sub-MIC antibiotics modulate biofilm formation through diverse mechanisms that intersect with c-di-GMP activity, including modulation of diguanylate cyclases and phosphodiesterases and through regulatory networks that intersect with quorum sensing and different two-component systems. These responses influence multiple components of biofilm matrix- and biofilm-associated physiology, including exopolysaccharides, extracellular DNA, cell surface proteins, secretion systems, and stress-adaptive multicellular behavior. Conclusions: By positioning c-di-GMP as an integrative, but context-dependent, signaling hub linking antibiotic-induced stress, metabolic adaptation, persistence, and biofilm development, this review highlights critical mechanistic gaps and identifies potential therapeutic targets for disrupting biofilms and improving antibiotic efficacy.
- 15 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1023
Open AccessCyclic di-GMP Regulation of Antibiotic-Induced Biofilm Formation: A Systematic Review
Background/Objectives: Biofilm formation is a major bacterial survival strategy in response to antibiotic stress. The bacterial second messenger cyclic di-GMP (c-di-GMP) is a central regulator of biofilm development. Sub-minimum inhibitory concentrations (sub-MICs) of antibiotics act as biological active environmental cues that reprogram bacterial physiology and promote biofilm development. This systematic review synthesizes the current literature on sub-MIC antibiotic-induced biofilm formation across different pathogenic bacterial genera and critically evaluates the role of c-di-GMP. Methods: A systematic literature search was conducted in PubMed and Scopus for articles published from inception to 18 December 2025 using terms including “sub-MIC antibiotic” AND (“biofilm” OR “antibiotic-induced biofilm”) and a second search using “sub-MIC antibiotic” AND “biofilm” AND “c-di-GMP”. Reviews, commentaries, opinions, meta-analyses, systematic reviews, and non-English-language articles were excluded. Results: Collectively, 28 identified studies demonstrate that sub-MIC antibiotics modulate biofilm formation through diverse mechanisms that intersect with c-di-GMP activity, including modulation of diguanylate cyclases and phosphodiesterases and through regulatory networks that intersect with quorum sensing and different two-component systems. These responses influence multiple components of biofilm matrix- and biofilm-associated physiology, including exopolysaccharides, extracellular DNA, cell surface proteins, secretion systems, and stress-adaptive multicellular behavior. Conclusions: By positioning c-di-GMP as an integrative, but context-dependent, signaling hub linking antibiotic-induced stress, metabolic adaptation, persistence, and biofilm development, this review highlights critical mechanistic gaps and identifies potential therapeutic targets for disrupting biofilms and improving antibiotic efficacy.
- Open Access
- 2 September 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (9)
Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains
Clostridioides difficile infection (CDI) has limited antibiotic treatment options, with fidaxomicin being the guideline-preferred antibiotic. C. E. Kaple, S. N. Redmond, J. L. Cadum, B. Hausman, et al. (Antimicrob Agents Chemother 0:e00130-26, 2026, https://doi.org/10.1128/aac.00130-26 ) describe a case of clinical failure in an elderly patient with CDI treated with a pulsed-taper fidaxomicin regimen, in which the MIC increased from 0.05 μg/mL at baseline to 32 μg/mL in isolates recovered during relapse. Relapsing symptoms were eventually resolved only after switching to oral vancomycin. This case, together with other recent clinical reports, may be the tip of the iceberg, signaling that fidaxomicin-resistant C. difficile can arise during treatment and contribute to clinical failure. It further challenges the assumption that high colonic drug concentrations mitigate resistance and underscores the need for improved surveillance and the development of clinically applicable molecular diagnostics to detect fidaxomicin resistance in CDI patient samples.
- 2 September 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (9)
Open AccessCase Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains
Clostridioides difficile infection (CDI) has limited antibiotic treatment options, with fidaxomicin being the guideline-preferred antibiotic. C. E. Kaple, S. N. Redmond, J. L. Cadum, B. Hausman, et al. (Antimicrob Agents Chemother 0:e00130-26, 2026, https://doi.org/10.1128/aac.00130-26 ) describe a case of clinical failure in an elderly patient with CDI treated with a pulsed-taper fidaxomicin regimen, in which the MIC increased from 0.05 μg/mL at baseline to 32 μg/mL in isolates recovered during relapse. Relapsing symptoms were eventually resolved only after switching to oral vancomycin. This case, together with other recent clinical reports, may be the tip of the iceberg, signaling that fidaxomicin-resistant C. difficile can arise during treatment and contribute to clinical failure. It further challenges the assumption that high colonic drug concentrations mitigate resistance and underscores the need for improved surveillance and the development of clinically applicable molecular diagnostics to detect fidaxomicin resistance in CDI patient samples.
- Open Access
- 4 February 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (2) , e0096025
Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent
Clostridioides difficile, a leading cause of hospital-acquired diarrhea, exerts its virulence through two co-regulated toxins, TcdA and TcdB. Despite their pivotal roles, the discovery of inhibitors targeting their biosynthesis is underexplored. Here, we present a high-throughput screening (HTS) platform designed to identify toxin synthesis inhibitors (TSIs) that minimally impact bacterial growth. The primary screen utilized a C. difficile reporter strain expressing secreted Nano-luciferase (secNluc) under the tcdA promoter, whereby inhibition of secNluc production indicates toxin biosynthesis inhibition. Screening the Prestwick Chemical Library at 10 and 100 µM identified several compounds that reduced secNluc activity. Through counter-screening, we eliminated compounds that caused spectral interference. Orthogonal dose-response assays assessing the effectiveness of inhibiting toxin production without affecting growth identified meclizine, an antihistamine, as the primary antivirulence candidate. Meclizine was confirmed as a TSI by showing that it reduced TcdA and TcdB protein levels, the cytopathic potential of cultures, and tcdA and tcdB transcription as determined by ELISA, cell-rounding assays, and RT-qPCR, respectively. Meclizine significantly altered central carbon metabolism in C. difficile , upregulating carbohydrate transport systems and the conversion of lactate to pyruvate, while downregulating glycolytic genes. These changes were associated with intracellular accumulation of glucose and pyruvate, metabolites known to negatively impact toxin production. Taken together, our findings underscore the utility of the above HTS platform to identify anti- C . difficile TSIs, which can serve as molecular and cellular probes, as well as chemical starting points for developing novel therapeutics for C. difficile infection.
- 4 February 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (2) , e0096025
Open AccessDevelopment of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent
Clostridioides difficile, a leading cause of hospital-acquired diarrhea, exerts its virulence through two co-regulated toxins, TcdA and TcdB. Despite their pivotal roles, the discovery of inhibitors targeting their biosynthesis is underexplored. Here, we present a high-throughput screening (HTS) platform designed to identify toxin synthesis inhibitors (TSIs) that minimally impact bacterial growth. The primary screen utilized a C. difficile reporter strain expressing secreted Nano-luciferase (secNluc) under the tcdA promoter, whereby inhibition of secNluc production indicates toxin biosynthesis inhibition. Screening the Prestwick Chemical Library at 10 and 100 µM identified several compounds that reduced secNluc activity. Through counter-screening, we eliminated compounds that caused spectral interference. Orthogonal dose-response assays assessing the effectiveness of inhibiting toxin production without affecting growth identified meclizine, an antihistamine, as the primary antivirulence candidate. Meclizine was confirmed as a TSI by showing that it reduced TcdA and TcdB protein levels, the cytopathic potential of cultures, and tcdA and tcdB transcription as determined by ELISA, cell-rounding assays, and RT-qPCR, respectively. Meclizine significantly altered central carbon metabolism in C. difficile , upregulating carbohydrate transport systems and the conversion of lactate to pyruvate, while downregulating glycolytic genes. These changes were associated with intracellular accumulation of glucose and pyruvate, metabolites known to negatively impact toxin production. Taken together, our findings underscore the utility of the above HTS platform to identify anti- C . difficile TSIs, which can serve as molecular and cellular probes, as well as chemical starting points for developing novel therapeutics for C. difficile infection.
- Open Access
- 2 April 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (4) , e0167924
The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae
Ibezapolstat (IBZ), a first-in-class antibiotic targeting the PolC-type DNA polymerase III alpha-subunit (PolC) in low G + C bacteria, is in clinical development for the treatment of Clostridioides difficile infection (CDI). In the phase 2 trials, IBZ had potent activity against C. difficile while sparing or causing regrowth of Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales, common commensal low G + C bacteria. The purpose of this study was to utilize in silico approaches to better interpret the narrower than expected IBZ spectrum of activity. IBZ susceptibility to human commensal microbiota was predicted using genomic analysis and PolC phylogenetic tree construction in relation to C. difficile and commensal low G + C bacteria. Protein structure prediction was performed using AlphaFold2 and binding pocket homology modeling was performed using Schrodinger Maestro and UCSF ChimeraX. An amino acid phylogenetic tree identified certain residues that were phylogenetically variant in Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales and conserved in C. difficile . Chemical modeling showed that these residues ablated key PolC•IBZ predicted interactions including two lysine “ gates ” ( CdiPolC Lys1148 and CdiPolC Lys1327) that “ latch ” onto the compound; an “ anchoring ” interaction ( CdiPolC Thr1331) to the central moiety; and a stabilized set of C. difficile sensitizer residues ( CdiPolC Thr1291 and CdiPolC Lys1292) that resulted in the prolonged inhibition of a catalytic residue ( CdiPolC Asp1090). The observed IBZ sparing of Lachnospiraceae, Oscillospiraceae, and Erysipelotrichaceae/Coprobacillaceae was predicted using in silico techniques. Further studies that confirm a PolC structural basis for the IBZ narrower than expected activity are needed to confirm these in silico phylogenetic and chemical modeling data.
- 2 April 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (4) , e0167924
Open AccessThe microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae
Ibezapolstat (IBZ), a first-in-class antibiotic targeting the PolC-type DNA polymerase III alpha-subunit (PolC) in low G + C bacteria, is in clinical development for the treatment of Clostridioides difficile infection (CDI). In the phase 2 trials, IBZ had potent activity against C. difficile while sparing or causing regrowth of Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales, common commensal low G + C bacteria. The purpose of this study was to utilize in silico approaches to better interpret the narrower than expected IBZ spectrum of activity. IBZ susceptibility to human commensal microbiota was predicted using genomic analysis and PolC phylogenetic tree construction in relation to C. difficile and commensal low G + C bacteria. Protein structure prediction was performed using AlphaFold2 and binding pocket homology modeling was performed using Schrodinger Maestro and UCSF ChimeraX. An amino acid phylogenetic tree identified certain residues that were phylogenetically variant in Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales and conserved in C. difficile . Chemical modeling showed that these residues ablated key PolC•IBZ predicted interactions including two lysine “ gates ” ( CdiPolC Lys1148 and CdiPolC Lys1327) that “ latch ” onto the compound; an “ anchoring ” interaction ( CdiPolC Thr1331) to the central moiety; and a stabilized set of C. difficile sensitizer residues ( CdiPolC Thr1291 and CdiPolC Lys1292) that resulted in the prolonged inhibition of a catalytic residue ( CdiPolC Asp1090). The observed IBZ sparing of Lachnospiraceae, Oscillospiraceae, and Erysipelotrichaceae/Coprobacillaceae was predicted using in silico techniques. Further studies that confirm a PolC structural basis for the IBZ narrower than expected activity are needed to confirm these in silico phylogenetic and chemical modeling data.
- 5 December 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (12) , e0120624
Fidaxomicin resistance in Clostridioides difficile : a systematic review and predictive modeling with RNA polymerase binding sites
Fidaxomicin (FDX), an RNA polymerase (RNAP) inhibitor antibiotic, is a guideline-recommended therapy for Clostridioides difficile infection. Mutations associated with reduced FDX minimum inhibitory concentrations (MICs) have been identified. However, the molecular characterization of these mutations on FDX binding and the development of FDX resistance have not been studied. The purpose of this systematic review was to identify FDX resistance in C. difficile isolates and determine whether single nucleotide polymorphisms associated with increased FDX MIC aligned with the RNAP binding pocket interacting residues. A systematic literature search was done in PubMed (1991–2023) with identified articles and their bibliographies searched for papers that included C. difficile genetic mutations and increased FDX MIC. Visualization of FDX-RNAP interactions was performed on Schrödinger Maestro using the publicly available C. difficile RNAP with fidaxomicin sequence (code 7L7B) on the Protein Data Bank. Seven articles were identified after applying inclusion and exclusion criteria. The most common mutation in clinical and laboratory isolates was at position V1143 of the β subunit, which accounted for approximately 50% of the identified mutations. Most other mutations occurred within the β′ subunit of RNAP. Approximately one-third of the identified mutation aligned directly with FDX interacting residues with C. difficile RNAP (7/20) with most of the remainder occurring within 5 Å of the binding residues. C. difficile strains with elevated FDX MIC align closely with the known RNAP binding residues. These data demonstrate the potential to identify genomic methods to identify emerging FDX resistance.
- 5 December 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (12) , e0120624
Fidaxomicin resistance in Clostridioides difficile : a systematic review and predictive modeling with RNA polymerase binding sites
Fidaxomicin (FDX), an RNA polymerase (RNAP) inhibitor antibiotic, is a guideline-recommended therapy for Clostridioides difficile infection. Mutations associated with reduced FDX minimum inhibitory concentrations (MICs) have been identified. However, the molecular characterization of these mutations on FDX binding and the development of FDX resistance have not been studied. The purpose of this systematic review was to identify FDX resistance in C. difficile isolates and determine whether single nucleotide polymorphisms associated with increased FDX MIC aligned with the RNAP binding pocket interacting residues. A systematic literature search was done in PubMed (1991–2023) with identified articles and their bibliographies searched for papers that included C. difficile genetic mutations and increased FDX MIC. Visualization of FDX-RNAP interactions was performed on Schrödinger Maestro using the publicly available C. difficile RNAP with fidaxomicin sequence (code 7L7B) on the Protein Data Bank. Seven articles were identified after applying inclusion and exclusion criteria. The most common mutation in clinical and laboratory isolates was at position V1143 of the β subunit, which accounted for approximately 50% of the identified mutations. Most other mutations occurred within the β′ subunit of RNAP. Approximately one-third of the identified mutation aligned directly with FDX interacting residues with C. difficile RNAP (7/20) with most of the remainder occurring within 5 Å of the binding residues. C. difficile strains with elevated FDX MIC align closely with the known RNAP binding residues. These data demonstrate the potential to identify genomic methods to identify emerging FDX resistance.
- Open Access
- 10 October 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (11) , ofae588
Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Specific Ribotypes
Reduced vancomycin (VAN) susceptibility in clinical Clostridioides difficile isolates is correlated with poor clinical outcomes. However, factors associated with infection with these strains are unknown. The goal of this study was to determine risk factors for reduced VAN susceptibility among clinical isolates of C. difficile. This multicenter cohort study included adults with C. difficile infection (CDI) between 2016-21. Clinical C. difficile isolates underwent agar dilution VAN susceptibility testing and ribotyping. Reduced susceptibility was defined as a minimum inhibitory concentration (MIC) > 2 µg/mL. Medical charts were reviewed for host, pathogen, and hospital characteristics and assessed for predictors of reduced VAN susceptibility. Five hundred and ninety-four hospitalized patients with CDI between 2016-21 (female: 57%, >65 years old: 55%, white/non-Hispanic: 59%, non-severe CDI episode: 53%) were identified. Of 594 isolates, 173 (29%) had reduced VAN susceptibility (MIC50: 2 µg/mL, MIC90: 4 µg/mL). In multivariable analysis, ribotype (RT) 027 (odds ratio [OR]: 13.4; 95% confidence interval [CI]: 7.7-23.4; p<0.0001) and RT 255 (OR: 2.9; 95% CI: 1.4-6.1; p=0.005) were positively associated with reduced VAN susceptibility while RT 014-020 (OR: 0.41; 95% CI: 0.21-0.80; p=0.0092) was more likely to be susceptible to VAN. The prevalence of strains with reduced VAN susceptibility increased over time (p=0.0163). No patient- or hospitalization-specific variable predicted infection with reduced susceptibility strain. Certain ribotypes, including RT 027, were the sole independent risk factors for reduced VAN susceptibility. Increased clinical surveillance of these strains, especially RT 027, and their antibiotic susceptibly is warranted to inform prescribing practices.
- 10 October 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (11) , ofae588
Open AccessReduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Specific Ribotypes
Reduced vancomycin (VAN) susceptibility in clinical Clostridioides difficile isolates is correlated with poor clinical outcomes. However, factors associated with infection with these strains are unknown. The goal of this study was to determine risk factors for reduced VAN susceptibility among clinical isolates of C. difficile. This multicenter cohort study included adults with C. difficile infection (CDI) between 2016-21. Clinical C. difficile isolates underwent agar dilution VAN susceptibility testing and ribotyping. Reduced susceptibility was defined as a minimum inhibitory concentration (MIC) > 2 µg/mL. Medical charts were reviewed for host, pathogen, and hospital characteristics and assessed for predictors of reduced VAN susceptibility. Five hundred and ninety-four hospitalized patients with CDI between 2016-21 (female: 57%, >65 years old: 55%, white/non-Hispanic: 59%, non-severe CDI episode: 53%) were identified. Of 594 isolates, 173 (29%) had reduced VAN susceptibility (MIC50: 2 µg/mL, MIC90: 4 µg/mL). In multivariable analysis, ribotype (RT) 027 (odds ratio [OR]: 13.4; 95% confidence interval [CI]: 7.7-23.4; p<0.0001) and RT 255 (OR: 2.9; 95% CI: 1.4-6.1; p=0.005) were positively associated with reduced VAN susceptibility while RT 014-020 (OR: 0.41; 95% CI: 0.21-0.80; p=0.0092) was more likely to be susceptible to VAN. The prevalence of strains with reduced VAN susceptibility increased over time (p=0.0163). No patient- or hospitalization-specific variable predicted infection with reduced susceptibility strain. Certain ribotypes, including RT 027, were the sole independent risk factors for reduced VAN susceptibility. Increased clinical surveillance of these strains, especially RT 027, and their antibiotic susceptibly is warranted to inform prescribing practices.
- Open Access
- 27 September 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (11) , 107839
Chemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets
- 27 September 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (11) , 107839
Open AccessChemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets
- Open Access
- 10 April 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (5) , 1612-1623
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target
Fusobacterium nucleatum, a pathobiont inhabiting the oral cavity, contributes to opportunistic diseases, such as periodontal diseases and gastrointestinal cancers, which involve microbiota imbalance. Broad-spectrum antimicrobial agents, while effective against F. nucleatum infections, can exacerbate dysbiosis. This necessitates the discovery of more targeted narrow-spectrum antimicrobial agents. We therefore investigated the potential for the fusobacterial enoyl-ACP reductase II (ENR II) isoenzyme FnFabK (C4N14_ 04250) as a narrow-spectrum drug target. ENRs catalyze the rate-limiting step in the bacterial fatty acid synthesis pathway. Bioinformatics revealed that of the four distinct bacterial ENR isoforms, F. nucleatum specifically encodes FnFabK. Genetic studies revealed that fabK was indispensable for F. nucleatum growth, as the gene could not be deleted, and silencing of its mRNA inhibited growth under the test conditions. Remarkably, exogenous fatty acids failed to rescue growth inhibition caused by the silencing of fabK. Screening of synthetic phenylimidazole analogues of a known FabK inhibitor identified an inhibitor (i.e., 681) of FnFabK enzymatic activity and F. nucleatum growth, with an IC50 of 2.1 μM (1.0 μg/mL) and a MIC of 0.4 μg/mL, respectively. Exogenous fatty acids did not attenuate the activity of 681 against F. nucleatum. Furthermore, FnFabK was confirmed as the intracellular target of 681 based on the overexpression of FnFabK shifting MICs and 681-resistant mutants having amino acid substitutions in FnFabK or mutations in other genetic loci affecting fatty acid biosynthesis. 681 had minimal activity against a range of commensal flora, and it was less active against streptococci in physiologic fatty acids. Taken together, FnFabK is an essential enzyme that is amenable to drug targeting for the discovery and development of narrow-spectrum antimicrobial agents.
- 10 April 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (5) , 1612-1623
Open AccessEvaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target
Fusobacterium nucleatum, a pathobiont inhabiting the oral cavity, contributes to opportunistic diseases, such as periodontal diseases and gastrointestinal cancers, which involve microbiota imbalance. Broad-spectrum antimicrobial agents, while effective against F. nucleatum infections, can exacerbate dysbiosis. This necessitates the discovery of more targeted narrow-spectrum antimicrobial agents. We therefore investigated the potential for the fusobacterial enoyl-ACP reductase II (ENR II) isoenzyme FnFabK (C4N14_ 04250) as a narrow-spectrum drug target. ENRs catalyze the rate-limiting step in the bacterial fatty acid synthesis pathway. Bioinformatics revealed that of the four distinct bacterial ENR isoforms, F. nucleatum specifically encodes FnFabK. Genetic studies revealed that fabK was indispensable for F. nucleatum growth, as the gene could not be deleted, and silencing of its mRNA inhibited growth under the test conditions. Remarkably, exogenous fatty acids failed to rescue growth inhibition caused by the silencing of fabK. Screening of synthetic phenylimidazole analogues of a known FabK inhibitor identified an inhibitor (i.e., 681) of FnFabK enzymatic activity and F. nucleatum growth, with an IC50 of 2.1 μM (1.0 μg/mL) and a MIC of 0.4 μg/mL, respectively. Exogenous fatty acids did not attenuate the activity of 681 against F. nucleatum. Furthermore, FnFabK was confirmed as the intracellular target of 681 based on the overexpression of FnFabK shifting MICs and 681-resistant mutants having amino acid substitutions in FnFabK or mutations in other genetic loci affecting fatty acid biosynthesis. 681 had minimal activity against a range of commensal flora, and it was less active against streptococci in physiologic fatty acids. Taken together, FnFabK is an essential enzyme that is amenable to drug targeting for the discovery and development of narrow-spectrum antimicrobial agents.